Join the fight to lower drug prices

VIDEO: Why Are Prescription Drug Prices So High?

The Truth About Innovation & Drug Prices

Read our report

Tell us how high drug prices are hurting you.

Share your story

Patients For Affordable Drugs is the only independent national patient organization focused exclusively on achieving policy changes to lower the price of prescription drugs.

We do not accept funding from organizations that profit from the development or distribution of prescription drugs.

Learn more

“Let’s do what we talked about for all the years I was down here in this body, in Congress. Let’s give Medicare the power to save hundreds of billions of dollars by negotiating lower drug prescription prices… It’s within our power to do it. Let’s do it now.”

President Joe Biden
April 2021, Joint Address to Congress

“One of my top priorities from my chairmanship of the Senate Finance Committee — to lower drug prices — will continue, in addition to other measures within the jurisdiction of the Judiciary Committee where I’ll advance my bipartisan legislation to stop anti-competitive practices in the pharmaceutical drug industry.”

Senator Chuck Grassley (R-IA)
February 2021

"Patients for Affordable Drugs brings a much-needed voice and perspective to the debate about lowering the cost of prescription drugs. People across the country are worried about high drug prices, and many are struggling because they can’t afford their medications. We look forward to working with P4AD to solve this critical issue."

Nancy LeaMond, AARP EVP, Chief Advocacy & Engagement Officer
March 2017

Solutions

We can have both innovation and lower prescription drug prices

There's more
Medicare should be able to negotiate lower costs for patients
Learn more
Generic versions of drugs should be available sooner to compete with brand names
Learn more
Pharmacy benefit managers should disclose their secret deals so we get the full benefit
Learn more

JOIN US

Patients For Affordable Drugs is the only independent national patient organization focused exclusively on achieving policy changes to lower the price of prescription drugs.